Compare Citius Pharmaceuticals Inc (CTXR) vs Eos Energy Enterprises Inc (EOSE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Eos Energy Enterprises Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Eos Energy Enterprises Inc trades at $2.66 (market cap $1.01B). The key difference: Eos Energy Enterprises Inc is far larger — about 74.2× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 39,626,541). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Eos Energy Enterprises Inc for 16 Days on average.
| CTXR | EOSE | |
|---|---|---|
Market Cap | $13.62M | $1.01B |
Volume | 132,438 | 39,626,541 |
Sector | Health | Industrials |
52-Week High | $1.82 | $19.19 |
52-Week Low | $0.48 | $2.77 |
Typical Hold Time | 16 Days | 16 Days |
Enterprise Value | $3.79M | $1.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Eos Energy Enterprises (EOSE) trades at $2.645, down 14.68% in the last session, reflecting significant volatility amid mixed quarterly results. The company shows rapid revenue growth but deep losses, with a -246.76% net income margin in 2026. Recent developments include a $87 million DOE loan advance and a partnership with Google for a West Virginia energy project, highlighting growth potential in long-duration energy storage.
The outlook is bifurcated: strong revenue growth and strategic partnerships offer upside, but persistent losses and high debt-to-asset ratio of 91.87% pose substantial risks. Analyst consensus is cautious with a $7.10 price target, suggesting 168% potential upside, yet the bearish technical signal and negative cash flows from operations warrant careful monitoring of execution and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →
